Trial Profile
A MULTIARM, OPEN LABEL, RANDOMIZED PHASE II STUDY OF MLN9708 PLUS ORAL DEXAMETHASONE or PLUS ORAL CYCLOPHOSPHAMIDE AND DEXAMETHASONE or PLUS ORAL THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Bendamustine; Cyclophosphamide; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 Dec 2020 Updated results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2020 Results of post-hoc analysis presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 04 Nov 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2023.